Duo Oncology focuses on advancing cancer treatment through innovative technologies that harness the power of the immune system. Their proprietary platform is designed to identify and develop novel therapeutic agents that can effectively target and eliminate cancer cells. By utilizing a combination of advanced biomarker discovery and cutting-edge drug development techniques, Duo Oncology aims to create personalized treatment options that enhance patient outcomes and minimize side effects.

The company emphasizes the importance of precision medicine in oncology, leveraging data-driven approaches to tailor therapies to individual patient profiles. Their research includes the exploration of unique mechanisms of action that can disrupt cancer cell survival and proliferation. Through rigorous scientific validation and clinical testing, Duo Oncology is committed to bringing transformative therapies to market that address unmet needs in cancer care, ultimately striving to improve the quality of life for patients battling this disease.

United States

Duo Oncology, founded by oncologists, is developing tumor-penetrating nanomedicines to upgraded the foundations of cancer medicine.
Duo's patented platform prodrug chemistry releases creates nanomedicines that penetrate established tumors to reduce toxicity and improve patient outcomes.

Duo Oncology

Company Details